TipRanks on MSN

Nuvation Bio enrolls first patient in G203 study

Nuvation Bio (NUVB) announced enrollment of the first patient into part 2 of G203, a global, randomized study evaluating the efficacy and safety ...

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203 ...
The Globe and Mail

Nuvation Bio’s Phase 2 Study on Safusidenib: A Potential Game-Changer for IDH1 Mutant Glioma

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Nuvation Bio Inc. is currently conducting ...